Erratum: Molecular Immunology Corrigendum to “Antitumor effects obtained by autologous Lewis lung cancer cell vaccine engineered to secrete mouse Interleukin 27 by means of cationic liposome” [Mol. Immunol. 55 (3-4) (2013) 264–274](S0161589013000448)(10.1016/j.molimm.2013.02.006);Antitumor effects obtained by autologous Lewis lung cancer cell vaccine engineered to secrete mouse Interleukin 27 by means of cationic liposome

Molecular Immunology

Volumn 55, Issue 3-4, 2013, Pages 264-274

  Zhang, Junfeng ^a   Tian, Hongwei ^a   Li, Can ^a   Cheng, Lin ^a   Zhang, Shuang ^a   Zhang, Xiaomei ^a   Wang, Ruibo ^a   Xu, Fen ^a   Dai, Lei ^a   Shi, Gang ^a   Chen, Xiaolei ^a   Li, Yiming ^a   Du, Tao ^a   Deng, Jie ^a   Liu, Yu ^a   Yang, Yang ^a   Wei, Yuquan ^a   Deng, Hongxin ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Cationic liposome; IL 27; Immunotherapy; LL 2; Tumor cell vaccine

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; AUTOLOGOUS LEWIS LUNG CANCER CELL VACCINE; CHOLESTEROL; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 27; LIPOSOME; TUMOR ANTIGEN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DEPLETION; FEMALE; GENE; IMMUNE RESPONSE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; X RAY;

MUS; RATTUS;

EID: 84877600913     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2021.11.006     Document Type: Erratum

References (65)

1. Abdallah B., Sachs L., Demeneix B.A. Non-viral gene transfer: applications in developmental biology and gene therapy. Biology of the Cell 1995, 85:1-7.
2. Airoldi I., Ribatti D. Regulation of angiostatic chemokines driven by IL-12 and IL-27 in human tumors. Journal of Leukocyte Biology 2011, 90:875-882.
3. Allison S.D., Anchordoquy T.J. Mechanisms of protection of cationic lipid-DNA complexes during lyophilization. Journal of Pharmaceutical Sciences 2000, 89:682-691.
4. Anchordoquy T.J., Girouard L.G., Carpenter J.F., Kroll D.J. Stability of lipid/DNA complexes during agitation and freeze-thawing. Journal of Pharmaceutical Sciences 1998, 87:1046-1051.
5. Armstrong T.K., Zhang Y., Patel M.M., Lentz Y.K., Anchordoquy T.J. The stability of lyophilized lipid/DNA complexes during prolonged storage. Journal of Pharmaceutical Sciences 2004, 93:2259-2273.
6. Artis D., Villarino A., Silverman M., He W., Thornton E.M., Mu S., Summer S., Covey T.M., Huang E., Yoshida H. The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. The Journal of Immunology 2004, 173:5626.
7. Asada H., Kishida T., Hirai H., Satoh E., Ohashi S., Takeuchi M., Kubo T., Kita M., Iwakura Y., Imanishi J. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex. Molecular Therapy 2002, 5:609-616.
8. Batten M., Li J., Yi S., Kljavin N.M., Danilenko D.M., Lucas S., Lee J., de Sauvage F.J., Ghilardi N. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nature Immunology 2006, 7:929-936.
9. Blezinger P., Wang J., Gondo M., Quezada A., Mehrens D., French M., Singhal A., Sullivan S., Rolland A., Ralston R. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nature Biotechnology 1999, 17:343-348.
10. Boon T., Coulie P.G., Van den Eynde B. Tumor antigens recognized by T cells. Immunology Today 1997, 18:267-268.
11. Cao Y., Doodes P.D., Glant T.T., Finnegan A. IL-27 induces a Th1 immune response and susceptibility to experimental arthritis. The Journal of Immunology 2008, 180:922-930.
12. Chiang C.L.L., Benencia F., Coukos G. Whole Tumor Antigen Vaccines 2010, vol. 22. Elsevier, 132-143.
13. Chiyo M., Shimozato O., Yu L., Kawamura K., Iizasa T., Fujisawa T., Tagawa M. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. International Journal of Cancer 2005, 115:437-442.
14. Cocco C., Giuliani N., Di Carlo E., Ognio E., Storti P., Abeltino M., Sorrentino C., Ponzoni M., Ribatti D., Airoldi I. Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clinical Cancer Research 2010, 16:4188-4197.
15. Fitzgerald D.C., Ciric B., Touil T., Harle H., Grammatikopolou J., Sarma J.D., Gran B., Zhang G.X., Rostami A. Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. The Journal of Immunology 2007, 179:3268-3275.
16. Hisada M., Kamiya S., Fujita K., Belladonna M.L., Aoki T., Koyanagi Y., Mizuguchi J., Yoshimoto T. Potent antitumor activity of interleukin-27. Cancer Research 2004, 64:1152.
17. Ho M.Y., Leu S.J.J., Sun G.H., Tao M.H., Tang S.J., Sun K.H. IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. The Journal of Immunology 2009, 183:6217-6226.
18. Horton H.M., Anderson D., Hernandez P., Barnhart K.M., Norman J.A., Parker S.E. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon α. Proceedings of the National Academy of Sciences 1999, 96:1553.
19. Hu P., Hu H.D., Chen M., Peng M.L., Tang L., Tang K.F., Matsui M., Belladonna M.L., Yoshimoto T., Zhang D.Z. Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Molecular Immunology 2009, 46:1654-1662.
20. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA: A Cancer Journal for Clinicians 2010, 60:277-300.
21. Klippstein R., Pozo D. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine: Nanotechnology, Biology and Medicine 2010, 6:523-529.
22. Liu J., Wei Y., Yang L., Zhao X., Tian L., Hou J., Niu T., Liu F., Jiang Y., Hu B. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 2003, 102:1815-1823.
23. Lundstrom K. Latest development in viral vectors for gene therapy. Trends in Biotechnology 2003, 21:117-122.
24. Luten J., Van Nostrum C.F., De Smedt S.C., Hennink W.E. Biodegradable polymers as non-viral carriers for plasmid DNA delivery. Journal of Controlled Release 2008, 126:97-110.
25. Matsui M., Moriya O., Belladonna M.L., Kamiya S., Lemonnier F.A., Yoshimoto T., Akatsuka T. Adjuvant activities of novel cytokines, interleukin-23 (IL-23) and IL-27, for induction of hepatitis C virus-specific cytotoxic T lymphocytes in HLA-A* 0201 transgenic mice. Journal of Virology 2004, 78:9093-9104.
26. Morishima N., Owaki T., Asakawa M., Kamiya S., Mizuguchi J., Yoshimoto T. Augmentation of effector CD8+ T cell generation with enhanced granzyme B expression by IL-27. The Journal of Immunology 2005, 175:1686-1693.
27. Murray J.S. How the MHC selects Th1/Th2 immunity. Immunology Today 1998, 19:157-162.
28. Owaki T., Asakawa M., Morishima N., Hata K., Fukai F., Matsui M., Mizuguchi J., Yoshimoto T. A role for IL-27 in early regulation of Th1 differentiation. The Journal of Immunology 2005, 175:2191-2200.
29. Parekh K., Ramachandran S., Cooper J., Bigner D., Patterson A., Mohanakumar T. Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes. Lung Cancer 2005, 47:17-29.
30. + T Cells. Immunity 2002, 16:779-790.
31. Porgador A., Tzehoval E., Vadai E., Feldman M., Eisenbach L. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases. Cancer Research 1995, 55:4941.
32. Pot C., Jin H., Awasthi A., Liu S.M., Lai C.Y., Madan R., Sharpe A.H., Karp C.L., Miaw S.C., Ho I.C. Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. The Journal of Immunology 2009, 183:797-801.
33. Pupo E., Padrón A., Santana E., Sotolongo J., Quintana D., Dueñas S., Duarte C., de la Rosa M.C., Hardy E. Preparation of plasmid DNA-containing liposomes using a high-pressure homogenization-extrusion technique. Journal of Controlled Release 2005, 104:379-396.
34. Puppo F., Brenci S., Montinaro E., Lanza L., Contini P., Scudeletti M., Indiveri F. Inhibition of alloreactive cytotoxic T cell activity by HIV-positive sera: potential role of circulating soluble HLA class I molecules. AIDS Research and Human Retroviruses 1994, 10:1061-1064.
35. Robinson D.S., O'Garra A. Further checkpoints in Th1 development. Immunity 2002, 16:755-758.
36. Romagnani S. The Th1/Th2 paradigm. Immunology Today 1997, 18:263-266.
37. Rosenberg S.A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunology Today 1997, 18:175-182.
38. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nature Medicine 2004, 10:909-915.
39. Salcedo R., Stauffer J.K., Lincoln E., Back T.C., Hixon J.A., Hahn C., Shafer-Weaver K., Malyguine A., Kastelein R., Wigginton J.M. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. The Journal of Immunology 2004, 173:7170-7182.
40. Schneider R., Yaneva T., Beauseigle D., El-Khoury L., Arbour N. IL-27 increases the proliferation and effector functions of human naïve CD8+ T lymphocytes and promotes their development into Tc1 cells. European Journal of Immunology 2011, 41:47-59.
41. Schwartz R.H. T cell clonal anergy. Current Opinion in Immunology 1997, 9:351-357.
42. Shimizu M., Shimamura M., Owaki T., Asakawa M., Fujita K., Kudo M., Iwakura Y., Takeda Y., Luster A.D., Mizuguchi J. Antiangiogenic and antitumor activities of IL-27. The Journal of Immunology 2006, 176:7317.
43. Soiffer R., Lynch T., Mihm M., Jung K., Rhuda C., Schmollinger J.C., Hodi F.S., Liebster L., Lam P., Mentzer S. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proceedings of the National Academy of Sciences 1998, 95:13141.
44. Sonoke S., Ueda T., Fujiwara K., Sato Y., Takagaki K., Hirabayashi K., Ohgi T., Yano J. Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes. Cancer Research 2008, 68:8843-8851.
45. Stabile L., Lyker J., Huang L., Siegfried J. Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy. Gene Therapy 2004, 11:325-335.
46. Stark G.R., Kerr I.M., Williams B.R.G., Silverman R.H., Schreiber R.D. How cells respond to interferons. Annual Review of Biochemistry 1998, 67:227-264.
47. Sun J., Dodd H., Moser E.K., Sharma R., Braciale T.J. CD4+ T cell help and innate-derived IL-27 induce Blimp-1-dependent IL-10 production by antiviral CTLs. Nature Immunology 2011, 12:327-334.
48. Tasaki K., Tagawa M., Gunji Y., Matsubara H., Takenaga K., Muramatsu M.A., Fujimura S., Suzuki T., Asano T., Ochiai T. Inhibition of experimental lung metastasis of murine colon carcinoma cells depends on the amount of interleukin-2 secreted from the transduced cells. Anticancer Research 1998, 18:813-817.
49. Tasaki K., Yoshida Y., Maeda T., Miyauchi M., Kawamura K., Takenaga K., Yamamoto H., Kouzu T., Asano T., Ochiai T., Sakiyama S., Tagawa M. Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells. Cancer Gene Therapy 2000, 7:247-254.
50. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nature Reviews Immunology 2003, 3:133-146.
51. Vergati M., Intrivici C., Huen N.Y., Schlom J., Tsang K.Y. Strategies for cancer vaccine development. Journal of Biomedicine and Biotechnology 2010, 2010.
52. Villarino A., Hibbert L., Lieberman L., Wilson E., Mak T., Yoshida H., Kastelein R.A., Saris C., Hunter C.A. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 2003, 19:645-655.
53. Villarino A.V., Huang E., Hunter C.A. Understanding the pro-and anti-inflammatory properties of IL-27. The Journal of Immunology 2004, 173:715-720.
54. Villarino A.V., Larkin J., Saris C.J.M., Caton A.J., Lucas S., Wong T., de Sauvage F.J., Hunter C.A. Positive and negative regulation of the IL-27 receptor during lymphoid cell activation. The Journal of Immunology 2005, 174:7684.
55. Wang S., Miyazaki Y., Shinozaki Y., Yoshida H. Augmentation of antigen-presenting and Th1-promoting functions of dendritic cells by WSX-1(IL-27R) deficiency. Journal of Immunology (Baltimore, Md.: 1950) 2007, 179:6421-6428.
56. Wei Y., Wang Q., Zhao X., Yang L., Tian L., Lu Y., Kang B., Lu C., Huang M., Lou Y. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nature Medicine 2000, 6:1160-1166.
57. Wei Y., Zhao X., Kariya Y., Fukata H., Teshigawara K., Uchida A. Induction of autologous tumor killing by heat treatment of fresh human tumor cells: involvement of γδ T cells and heat shock protein 70. Cancer Research 1996, 56:1104.
58. Wu H.Y., Quintana F.J., da Cunha A.P., Dake B.T., Koeglsperger T., Starossom S.C., Weiner H.L. In vivo induction of Tr1 Cells via mucosal dendritic cells and AHR signaling. PloS ONE 2011, 6:e23618.
59. Yoshida H., Hamano S., Senaldi G., Covey T., Faggioni R., Mu S., Xia M., Wakeham A.C., Nishina H., Potter J. WSX-1 Is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 2001, 15:569-578.
60. Yoshimoto T., Morishima N., Mizoguchi I., Shimizu M., Nagai H., Oniki S., Oka M., Nishigori C., Mizuguchi J. Antiproliferative activity of IL-27 on melanoma. The Journal of Immunology 2008, 180:6527.
61. Yoshimoto T., Okada K., Morishima N., Kamiya S., Owaki T., Asakawa M., Iwakura Y., Fukai F., Mizuguchi J. Induction of IgG2a class switching in B cells by IL-27. The Journal of Immunology 2004, 173:2479-2485.
62. Yoshimoto T., Yasuda K., Mizuguchi J., Nakanishi K. IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation. The Journal of Immunology 2007, 179:4415-4423.
63. Yoshimura T., Takeda A., Hamano S., Miyazaki Y., Kinjyo I., Ishibashi T., Yoshimura A., Yoshida H. Two-sided roles of IL-27: induction of Th1 differentiation on naive CD4+ T cells versus suppression of proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-dependent mechanism. The Journal of Immunology 2006, 177:5377.
64. Yuan Y., Tan J., Wang Y., Qian C., Zhang M. Chitosan nanoparticles as non-viral gene delivery vehicles based on atomic force microscopy study. Acta biochimica et biophysica Sinica 2009, 41:515-526.
65. Zhao J., Wen Y., Li Q., Wang Y., Wu H., Xu J., Chen X., Wu Y., Fan L., Yang H. A promising cancer gene therapy agent based on the matrix protein of vesicular stomatitis virus. The FASEB Journal 2008, 22:4272-4280.